These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20653328)

  • 1. Platelet P2Y₁₂ receptor inhibition: an update on clinical drug development.
    Vivas D; Angiolillo DJ
    Am J Cardiovasc Drugs; 2010; 10(4):217-26. PubMed ID: 20653328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the clinical development of cangrelor.
    Ueno M; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1069-77. PubMed ID: 20670184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
    Diehl P; Olivier C; Halscheid C; Helbing T; Bode C; Moser M
    Basic Res Cardiol; 2010 May; 105(3):379-87. PubMed ID: 19943165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
    Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cangrelor: a review on its mechanism of action and clinical development.
    Ferreiro JL; Ueno M; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Oct; 7(10):1195-201. PubMed ID: 19814662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents.
    Husted S
    Fundam Clin Pharmacol; 2009 Feb; 23(1):1-9. PubMed ID: 19267766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
    Bonello L; Tantry US; Marcucci R; Blindt R; Angiolillo DJ; Becker R; Bhatt DL; Cattaneo M; Collet JP; Cuisset T; Gachet C; Montalescot G; Jennings LK; Kereiakes D; Sibbing D; Trenk D; Van Werkum JW; Paganelli F; Price MJ; Waksman R; Gurbel PA;
    J Am Coll Cardiol; 2010 Sep; 56(12):919-33. PubMed ID: 20828644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADP receptors: inhibitory strategies for antiplatelet therapy.
    Cattaneo M
    Drug News Perspect; 2006 Jun; 19(5):253-9. PubMed ID: 16941047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.
    Capodanno D; Dharmashankar K; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):151-8. PubMed ID: 20136601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.
    Siller-Matula J; Schrör K; Wojta J; Huber K
    Thromb Haemost; 2007 Mar; 97(3):385-93. PubMed ID: 17334505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
    Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
    Höchtl T; Tentzeris I; Schrör K; Huber K
    Fundam Clin Pharmacol; 2012 Feb; 26(1):2-10. PubMed ID: 21831128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.